Support for Caregivers Means Better Care for Loved Ones with COPD

3 years ago

MISSION, KS / ACCESSWIRE / May 26, 2022 / (Family Features) Chances are you know someone who takes care of…

Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences

3 years ago

MINNEAPOLIS, MN / ACCESSWIRE / May 26, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic…

StageZero Life Sciences Announces Resignation of CFO

3 years ago

TORONTO, ON and RICHMOND, VA / ACCESSWIRE / May 26, 2022 / StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or…

Relief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. National Institutes of Health (NIH) Study of aviptadil in Critical COVID-19

3 years ago

GENEVA, SWITZERLAND / ACCESSWIRE / May 26, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF), (OTCQB:RLFTF, RLFTY) ("Relief"), a biopharmaceutical company…

Goodbody Health Announces the Launch of Its Core Health Diagnostic Check

3 years ago

VANCOUVER, BC / ACCESSWIRE / May 26, 2022 / Goodbody Health Inc. (CSE:GDBY) (OTCQB:GDBYF) ("Goodbody Health" or the "Company") is…

Empower Clinics Granted Accreditation For Mobile Covid-19 Testing Solutions Throughout British Columbia

3 years ago

New Certification Makes Empower's Testing Solutions Even More Convenient for its CustomersVANCOUVER, BC / ACCESSWIRE / May 26, 2022 /…

Europe’s Leading Psychedelic Conference Returns to Amsterdam

3 years ago

The OPEN Foundation invites you to the Interdisciplinary Conference on Psychedelic Research this September, featuring the world’s best experts on…

Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting

3 years ago

Meeting to highlight updated data from the Phase 1/2a study of CLN-081 CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) --…

Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting

3 years ago

Novel galectin-3-based mechanism of PD-1/PD-L1 checkpoint inhibitor resistance identified Galecto’s oral galectin-3 inhibitor candidate, GB1211, reverses galectin-3 induced blockade of…

Rakovina Therapeutics Inc. Announces Q1 2022 Financial Results and Provides Corporate Update

3 years ago

VANCOUVER, British Columbia, May 26, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company committed…